Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model

Vascular endothelial growth factor (VEGF) inhibition by the addition of bevacizumab to the chemotherapy regimen of metastatic colorectal cancer leads to an improved outcome. However, anti-angiogenic tumor therapy targeting a single factor may be limited by complementary mechanisms. Angiopoietin-2 (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Thomas, Freystein, Juana, Lucas, Henrike, Schmoll, Hans-Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719918/
https://www.ncbi.nlm.nih.gov/pubmed/31394786
http://dx.doi.org/10.3390/molecules24162865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719918/
https://www.ncbi.nlm.nih.gov/pubmed/31394786
http://dx.doi.org/10.3390/molecules24162865

Ejemplares similares